Cadence Pharma (CADX) Nov volatility elevated at 174 into PDUFA
Down)
Cadence Pharma (Nasdaq: CADX) closed at $10.06. CADX reported a Q3 loss of $11.4M. CADX's Acetavance (treatment for acute pain and fever) has a PDUFA on November 13. CADX November option implied volatility is at 174, December is at 128, May is at 110; above its 3-month average of 111 according to Track Data. Paul Foster
You May Also Be Interested In
- Savient Pharma (SVNT) Moves Higher with Volatility; Bumps Up Against Key Resistance Point
- Cree (CREE) Volatility Elevated as CFO Slide Continues
- Zynga (ZNGA) Holds Above Key Level Amid Increased Volatility; Still Well Below 50-Day SMA
Create E-mail Alert Related Categories
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
